Ipilimumab (MDX-010, Yervoy ®), an anti-CTLA-4 mAb, can block the molecules and lead to immune-mediated anticancer response for melanoma, renal cell carcinoma (RCC), colorectal cancer, malignant pleural mesothelioma, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC) 21. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.